{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:03:44Z","timestamp":1780095824875,"version":"3.54.0"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u03ccn Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PICT-2021-I-A-00733, PICT-2019-00583"],"award-info":[{"award-number":["PICT-2021-I-A-00733, PICT-2019-00583"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017700","name":"Fundaci\u00f3n Sales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>VACCIMEL is a therapeutic cancer vaccine composed of four irradiated allogeneic human melanoma cell lines rationally selected to cover a wide range of melanoma tumor-associated antigens (TAA). We previously demonstrated that vaccination in the adjuvant setting prolonged the distant-metastasis-free survival of cutaneous melanoma patients and that T cells reactive to TAA and the patient\u2019s private neoantigens increased during treatment. However, immune responses directed to vaccine antigens that may arise from VACCIMEL\u2019s somatic mutations and human polymorphisms remain unexplored. To study these immunogens, we performed whole-exome sequencing of paired tumor and germinal samples from four vaccinated patients and the vaccine cells. VACCIMEL variants were called by comparing the vaccine and the patient\u2019s exomes, and non-synonymous coding variants were used to predict T cell epitopes. Candidates were ranked based on their mRNA expression in VACCIMEL, predicted peptide-HLA (pHLA) presentation, and pHLA stability. Then, the immune responses to prioritized epitope candidates were tested using IFN\u03b3 ELISpot assays on vaccinated patients\u2019 PBMC samples. The comparison of the vaccine with the patients\u2019 germinal exomes revealed on average 9481 coding non-synonymous variants, suggesting that VACCIMEL offers a high number of potential antigens. Between 0,05 and 0,2% of these variants were also found in the tumors of three vaccinated patients; however, one patient with a high tumor mutational burden (TMB) shared 19,5% somatic variants. The assessment of T cell responses showed that vaccinated patients mounted highly diverse responses against VACCIMEL peptides. Notably, effector T cells targeting the patient\u2019s tumor antigens, comprising neoantigens and TAA, were found in higher frequencies than T cells targeting VACCIMEL-exclusive antigens. On the other hand, we observed that the immunogenic epitopes are not conserved across patients, despite sharing HLA and that immune responses fluctuate over time. Finally, a positive correlation between VACCIMEL antigen expression and the intensity of the T cell responses was found. Our results demonstrate that the immune system simultaneously responds to a high number of antigens, either vaccinal or private, proving that immune responses against epitopes not expressed in the patient\u2019s tumors were not detrimental to the immune recognition of neoantigens and TAA.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1496204","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T07:47:53Z","timestamp":1736236073000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["VACCIMEL, an allogeneic melanoma vaccine, efficiently triggers T cell immune responses against neoantigens and alloantigens, as well as against tumor-associated antigens"],"prefix":"10.3389","volume":"15","author":[{"given":"Ibel","family":"Carri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Trivino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika M.","family":"von Euw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Mordoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Marcela","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.3390\/cancers14215205","article-title":"Role of immunotherapy in the treatment of cancer: A systematic review","volume":"14","author":"Ling","year":"2022","journal-title":"Cancers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2014.911093","article-title":"Various ways to improve whole cancer cell vaccines","volume":"13","author":"Cicchelero","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02327-6","article-title":"Whole tumor cell-based vaccines: tuning the instruments to orchestrate an optimal antitumor immune response","volume":"129","author":"P\u00e9rez-Ba\u00f1os","year":"2023","journal-title":"Br J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.07.008","article-title":"Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies","volume":"133","author":"Li","year":"2009","journal-title":"Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3181eb33d7","article-title":"Cellular vaccine approaches","volume":"16","author":"Le","year":"2010","journal-title":"Cancer J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4161\/hv.26568","article-title":"Allogeneic tumor cell vaccines: the promise and limitations in clinical trials","volume":"10","author":"Srivatsan","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-21-0029","article-title":"In silico epitope prediction analyses highlight the potential for distracting antigen immunodominance with allogeneic cancer vaccines","volume":"1","author":"James","year":"2021","journal-title":"Cancer Res Commun"},{"key":"B9","article-title":"Protective antitumor immunity induced by immunization with completely allogeneic tumor cells","volume":"56","author":"Toes","year":"1996","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2019-0184","article-title":"Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy","volume":"21","author":"Zhao","year":"2020","journal-title":"Pharmacogenomics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00210-y","article-title":"Targeting public neoantigens for cancer immunotherapy","volume":"2","author":"Pearlman","year":"2021","journal-title":"Nat Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1084\/jem.20172188","article-title":"Shared cancer neoantigens: Making private matters public","volume":"215","author":"Klebanoff","year":"2018","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-061521-082114","article-title":"Targeting driver oncogenes and other public neoantigens using T cell receptor-based cellular therapy","volume":"7","author":"Martinov","year":"2023","journal-title":"Annu Rev Cancer Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150535","article-title":"Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma","volume":"132","author":"Kristensen","year":"2022","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.07.018","article-title":"Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma model","volume":"37","author":"Mac Keon","year":"2019","journal-title":"Vaccine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.842555","article-title":"An update of cutaneous melanoma patients treated in adjuvancy with the allogeneic melanoma vaccine VACCIMEL and presentation of a selected case report with in-transit metastases","volume":"13","author":"Mordoh","year":"2022","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00625","article-title":"Phase II study of adjuvant immunotherapy with the CSF-470 vaccine plus bacillus calmette-guerin plus recombinant human granulocyte macrophage-colony stimulating factor vs medium-dose interferon alpha 2B in stages IIB, IIC, and III cutaneous melanoma patients: A single institution, randomized study","volume":"8","author":"Mordoh","year":"2017","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01342","article-title":"Early events of the reaction elicited by CSF-470 melanoma vaccine plus adjuvants: an analysis of immune recruitment and cytokine release","volume":"8","author":"Pampena","year":"2017","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02531","article-title":"Dissecting the immune stimulation promoted by CSF-470 vaccine plus adjuvants in cutaneous melanoma patients: long term antitumor immunity and short term release of acute inflammatory reactants","volume":"9","author":"Pampena","year":"2018","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01147","article-title":"Evaluation of T-cell responses against shared melanoma associated antigens and predicted neoantigens in cutaneous melanoma patients treated with the CSF-470 allogeneic cell vaccine plus BCG and GM-CSF","volume":"11","author":"Podaza","year":"2020","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.37349\/ei.2023.00091","article-title":"Beyond MHC binding: immunogenicity prediction tools to refine neoantigen selection in cancer patients","volume":"3","author":"Carri","year":"2023","journal-title":"Explor Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3390\/cancers11091217","article-title":"Impact of tumor and immunological heterogeneity on the anti-cancer immune response","volume":"11","author":"Shembrey","year":"2019","journal-title":"Cancers"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1231734","article-title":"HEV-associated dendritic cells are observed in metastatic tumor-draining lymph nodes of cutaneous melanoma patients with longer distant metastasis-free survival after adjuvant immunotherapy","volume":"14","author":"Bravo","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1354710","article-title":"Vaccimel immunization is associated with enhanced response to treatment with anti-PD-1 monoclonal antibodies in cutaneous melanoma patients - a case reports study","volume":"15","author":"Mordoh","year":"2024","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02213","article-title":"Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCR\u03b2 Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood","author":"Aris","year":"2019","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.02.012","article-title":"Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis","volume":"176","author":"Petljak","year":"2019","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"eadj6367","DOI":"10.1126\/sciadv.adj6367","article-title":"Accurate prediction of HLA class II antigen presentation across all loci using tailored data acquisition and refined machine learning","volume":"9","author":"Nilsson","year":"2023","journal-title":"Sci Adv"},{"key":"B31","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41568-018-0060-1","article-title":"The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers","volume":"18","author":"Sondka","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad986","article-title":"COSMIC: a curated database of somatic variants and clinical data for cancer","volume":"52","author":"Sondka","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-8546-3_15","article-title":"HLA typing from short-read sequencing data with optiType","volume":"1802","author":"Szolek","year":"2018","journal-title":"Methods Mol Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac1011","article-title":"The IPD-IMGT\/HLA database","volume":"51","author":"Barker","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-5-19","article-title":"Monocyte-derived dendritic cells loaded with a mixture of apoptotic\/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes","volume":"5","author":"von Euw","year":"2007","journal-title":"J Transl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1360281","article-title":"IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognition","volume":"15","author":"Borch","year":"2024","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2001-3","article-title":"MuPeXI: prediction of neo-epitopes from tumor sequencing data","volume":"66","author":"Bjerregaard","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac902","article-title":"The cancer epitope database and analysis resource (CEDAR)","volume":"51","author":"Ko\u015falo\u011flu-Yal\u00e7\u0131n","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.644637","article-title":"NEPdb: A database of T-cell experimentally-validated neoantigens and pan-cancer predicted neoepitopes for cancer immunotherapy","volume":"12","author":"Xia","year":"2021","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.906352","article-title":"Dynamics of melanoma-associated epitope-specific CD8+ T cells in the blood correlate with clinical outcome under PD-1 blockade","volume":"13","author":"Gai\u00dfler","year":"2022","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0541","article-title":"Proteogenomics uncovers a vast repertoire of shared tumor-specific antigens in ovarian cancer","volume":"8","author":"Zhao","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"eade2886","DOI":"10.1126\/scitranslmed.ade2886","article-title":"Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy","volume":"16","author":"Li","year":"2024","journal-title":"Sci Transl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4239","article-title":"Intron retention is a source of neoepitopes in cancer","volume":"36","author":"Smart","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2021.100112","article-title":"MHC phosphopeptides: promising targets for immunotherapy of cancer and other chronic diseases","volume":"20","author":"Mahoney","year":"2021","journal-title":"Mol Cell Proteomics"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0280","article-title":"Identification of glycopeptides as posttranslationally modified neoantigens in leukemia","volume":"5","author":"Malaker","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104975","article-title":"The role of antigen expression in shaping the repertoire of HLA presented ligands","volume":"25","author":"Garcia Alvarez","year":"2022","journal-title":"iScience"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.103850","article-title":"Combined assessment of MHC binding and antigen abundance improves T cell epitope predictions","volume":"25","author":"Ko\u015falo\u011flu-Yal\u00e7\u0131n","year":"2022","journal-title":"iScience"},{"key":"B48","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41587-019-0322-9","article-title":"A large peptidome dataset improves HLA class I epitope prediction across most of the human population","volume":"38","author":"Sarkizova","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4313","article-title":"Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification","volume":"37","author":"Bulik-Sullivan","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e176740","DOI":"10.1172\/JCI176740","article-title":"Cancer neoepitopes viewed through negative selection and peripheral tolerance: a new path to cancer vaccines","volume":"134","author":"Srivastava","year":"2024","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00955","article-title":"Changes in the TCR\u03b2 Repertoire and tumor immune signature from a cutaneous melanoma patient immunized with the CSF-470 vaccine: A case report","volume":"9","author":"Aris","year":"2018","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000208258.79005.5f","article-title":"A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients","volume":"29","author":"Barrio","year":"2006","journal-title":"J Immunother"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1233376","article-title":"Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy","volume":"13","author":"Lee","year":"2023","journal-title":"Front Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"11.10.1","DOI":"10.1002\/0471250953.bi1110s43","article-title":"From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline","volume":"43","author":"Van der Auwera","year":"2013","journal-title":"Curr Protoc Bioinf"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp698","article-title":"Fast and accurate long-read alignment with Burrows-Wheeler transform","volume":"26","author":"Li","year":"2010","journal-title":"Bioinformatics"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/0471250953.bi1112s47","article-title":"BEDTools: the swiss-army tool for genome feature analysis","volume":"47","author":"Quinlan","year":"2014","journal-title":"Curr Protoc Bioinf"},{"key":"B57","doi-asserted-by":"publisher","first-page":"giab008","DOI":"10.1093\/gigascience\/giab008","article-title":"Twelve years of SAMtools and BCFtools","volume":"10","author":"Danecek","year":"2021","journal-title":"Gigascience"},{"key":"B58","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The ensembl variant effect predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-023-06045-0","article-title":"A genomic mutational constraint map using variation in 76,156 human genomes","volume":"625","author":"Chen","year":"2024","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","first-page":"btad756","DOI":"10.1093\/bioinformatics\/btad756","article-title":"Assigning mutational signatures to individual samples and individual somatic mutations with SigProfilerAssignment","volume":"39","author":"D\u00edaz-Gay","year":"2023","journal-title":"Bioinformatics"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3519","article-title":"Near-optimal probabilistic RNA-seq quantification","volume":"34","author":"Bray","year":"2016","journal-title":"Nat Biotechnol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2015.05.001","article-title":"An integrated genotyping approach for HLA and other complex genetic systems","volume":"76","author":"Nelson","year":"2015","journal-title":"Hum Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600582","article-title":"Pan-specific prediction of peptide-MHC class I complex stability, a correlate of T cell immunogenicity","volume":"197","author":"Rasmussen","year":"2016","journal-title":"J Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"861054","DOI":"10.1101\/861054","article-title":"Calling somatic SNVs and indels with mutect2","volume":"2019","author":"Benjamin","year":"2019","journal-title":"bioRxiv"},{"key":"B67","unstructured":"GitHub - bioinfo-pf-curie\/TMB: Tumor Mutational Burden\n          \n          2024"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2006.07.015","article-title":"Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials","volume":"315","author":"Moodie","year":"2006","journal-title":"J Immunol Methods"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1586\/14789450.2015.1040771","article-title":"The potential clinical impact of the tissue-based map of the human proteome","volume":"12","author":"Lindskog","year":"2015","journal-title":"Expert Rev Proteomics"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1082168","article-title":"Estimating tissue-specific peptide abundance from public RNA-Seq data","volume":"14","author":"Frentzen","year":"2023","journal-title":"Front Genet"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-005-4528-2","article-title":"Modeling the MHC class I pathway by combining predictions of proteasomal cleavage,TAP transport and MHC class I binding","volume":"62","author":"Tenzer","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.4.1741","article-title":"Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors","volume":"171","author":"Peters","year":"2003","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cels.2020.06.010","article-title":"MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing","volume":"11","author":"O\u2019Donnell","year":"2020","journal-title":"Cells"},{"key":"B74","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cels.2022.12.002","article-title":"Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8 T-cell epitopes","volume":"14","author":"Gfeller","year":"2023","journal-title":"Cell Syst"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx687","article-title":"Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma","volume":"29","author":"Ghorani","year":"2018","journal-title":"Ann Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.050","article-title":"MHC-I genotype restricts the oncogenic mutational landscape","volume":"171","author":"Marty","year":"2017","journal-title":"Cell"},{"key":"B77","unstructured":"Towards a mathematical foundation of immunology and amino acid chains\n          \n          1205.6031\n          \n            \n              Shen\n              WJ\n            \n            \n              Wong\n              HS\n            \n            \n              Xiao\n              QW\n            \n            \n              Guo\n              X\n            \n            \n              Smale\n              S\n            \n          \n          10.48550\/arXiv.1205.6031\n          arXiv\n          2012\n          2012"},{"key":"B78","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cels.2019.08.009","article-title":"Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade","volume":"9","author":"Richman","year":"2019","journal-title":"Cells"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002412","article-title":"Degenerate T-cell recognition of peptides on MHC molecules creates large holes in the T-cell repertoire","volume":"8","author":"Calis","year":"2012","journal-title":"PloS Comput Biol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcae002","article-title":"A large-scale study of peptide features defining immunogenicity of cancer neo-epitopes","volume":"6","author":"Wan","year":"2024","journal-title":"NAR Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp163","article-title":"Biopython: freely available Python tools for computational molecular biology and bioinformatics","volume":"25","author":"Cock","year":"2009","journal-title":"Bioinformatics"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-019-0686-2","article-title":"SciPy 1.0: fundamental algorithms for scientific computing in Python","volume":"17","author":"Virtanen","year":"2020","journal-title":"Nat Methods"},{"key":"B83","article-title":"Scikit-learn: machine learning in python","volume":"12","author":"Pedregosa","year":"2011","journal-title":"J Mach Learn Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1496204\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T07:47:58Z","timestamp":1736236078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1496204\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":83,"alternative-id":["10.3389\/fimmu.2024.1496204"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1496204","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"1496204"}}